Annual report
4887.TEDINET S100R1EV
Period2022-04-01 → 2023-03-31
Filed2023-06-27
StandardIFRS
ConsolidatedYes
Data checks20 of 20 passed
Key figures · 73
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥200.3bn | 2022-04-01 → 2023-03-31 | Cons. | Revenue IFRS |
| Revenue | ¥193.8bn | 2021-04-01 → 2022-03-31 | Cons. | Revenue IFRS |
| Operating income | ¥17.0bn | 2022-04-01 → 2023-03-31 | Cons. | Operating profit loss IFRS |
| Operating income | −¥35.9bn | 2021-04-01 → 2022-03-31 | Cons. | Operating profit loss IFRS |
| Profit before tax | ¥16.8bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss before tax IFRS |
| Profit before tax | −¥36.2bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss before tax IFRS |
| Net income (owners) | ¥12.7bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | −¥28.3bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income | ¥12.8bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss IFRS |
| Net income | −¥41.9bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss IFRS |
| Total assets | ¥364.2bn | at 2023-03-31 | Cons. | Assets IFRS |
| Total assets | ¥349.5bn | at 2022-03-31 | Cons. | Assets IFRS |
| Total liabilities | ¥151.4bn | at 2023-03-31 | Cons. | Liabilities IFRS |
| Total liabilities | ¥149.4bn | at 2022-03-31 | Cons. | Liabilities IFRS |
| Net assets / equity | ¥212.7bn | at 2023-03-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥200.1bn | at 2022-03-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥240.8bn | at 2021-03-31d | Cons. | Equity IFRS |
| Equity (owners) | ¥201.6bn | at 2023-03-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥190.1bn | at 2022-03-31 | Cons. | Equity attributable to owners of parent IFRS |
| Cash & equivalents | ¥33.1bn | at 2023-03-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥47.7bn | at 2022-03-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥54.3bn | at 2021-03-31d | Cons. | Cash and cash equivalents IFRS |
| Operating cash flow | ¥13.0bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥34.3bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in operating activities IFRS |
| Investing cash flow | −¥27.1bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥30.4bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in investing activities IFRS |
| Financing cash flow | −¥1.3bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | −¥11.3bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in financing activities IFRS |
| EPS (basic) | ¥289.25 | 2022-04-01 → 2023-03-31 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥-645.53 | 2021-04-01 → 2022-03-31 | Cons. | Basic earnings loss per share IFRS |
| EPS (diluted) | ¥288.6 | 2022-04-01 → 2023-03-31 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥-645.53 | 2021-04-01 → 2022-03-31 | Cons. | Diluted earnings loss per share IFRS |
| Net assets per share | ¥4,604.67 | at 2023-03-31 | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥4,340.32 | at 2022-03-31 | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Equity ratio | 55.4% | at 2023-03-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 54.4% | at 2022-03-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| ROE | 6.5% | 2022-04-01 → 2023-03-31 | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | -13.8% | 2021-04-01 → 2022-03-31 | Cons. | Rate of return on equity IFRS (5-year summary) |
| Employees | 3,393 | at 2023-03-31 | Cons. | Number of employees |
| Employees | 2,968 | at 2022-03-31 | Cons. | Number of employees |
| Revenue | ¥9.1bn | 2022-04-01 → 2023-03-31 | Standalone | Operating revenue1 |
| Revenue | ¥2.2bn | 2021-04-01 → 2022-03-31 | Standalone | Operating revenue1 |
| Operating income | ¥6.9bn | 2022-04-01 → 2023-03-31 | Standalone | Operating income |
| Operating income | −¥106m | 2021-04-01 → 2022-03-31 | Standalone | Operating income |
| Ordinary income | ¥6.9bn | 2022-04-01 → 2023-03-31 | Standalone | Ordinary income |
| Ordinary income | −¥230m | 2021-04-01 → 2022-03-31 | Standalone | Ordinary income |
| Profit before tax | ¥6.9bn | 2022-04-01 → 2023-03-31 | Standalone | Income before income taxes |
| Profit before tax | −¥30.2bn | 2021-04-01 → 2022-03-31 | Standalone | Income before income taxes |
| Net income | ¥6.9bn | 2022-04-01 → 2023-03-31 | Standalone | Profit loss |
| Net income | −¥30.3bn | 2021-04-01 → 2022-03-31 | Standalone | Profit loss |
| Total assets | ¥188.3bn | at 2023-03-31 | Standalone | Assets |
| Total assets | ¥192.0bn | at 2022-03-31 | Standalone | Assets |
| Total liabilities | ¥10.3bn | at 2023-03-31 | Standalone | Liabilities |
| Total liabilities | ¥15.5bn | at 2022-03-31 | Standalone | Liabilities |
| Net assets / equity | ¥178.0bn | at 2023-03-31 | Standalone | Net assets |
| Net assets / equity | ¥176.6bn | at 2022-03-31 | Standalone | Net assets |
| Cash and deposits | ¥1.1bn | at 2023-03-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥6.8bn | at 2022-03-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥158.64 | 2022-04-01 → 2023-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-691.14 | 2021-04-01 → 2022-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥158.28 | 2022-04-01 → 2023-03-31 | Standalone | Diluted earnings per share (5-year summary) |
| Dividend per share | ¥130 | 2022-04-01 → 2023-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥130 | 2021-04-01 → 2022-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥4,054.98 | at 2023-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥4,026.47 | at 2022-03-31 | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 94.3% | at 2023-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 91.8% | at 2022-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 3.9% | 2022-04-01 → 2023-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | -34.3% | 2021-04-01 → 2022-03-31 | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 43,791,000 | at 2023-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 43,791,000 | at 2022-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Employees | 73 | at 2023-03-31 | Standalone | Number of employees |
| Employees | 67 | at 2022-03-31 | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 23
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2023-03-31 | ¥0 |
| Japanreportable segment | employees | at 2023-03-31 | 2944 pure |
| Japanreportable segment | revenue | 2022-04-01 → 2023-03-31 | ¥163.7bn |
| Japanreportable segment | revenue external | 2022-04-01 → 2023-03-31 | ¥163.7bn |
| Japanreportable segment | segment profit | 2022-04-01 → 2023-03-31 | ¥16.1bn |
| USAreportable segment | employees | at 2023-03-31 | 449 pure |
| USAreportable segment | revenue | 2022-04-01 → 2023-03-31 | ¥36.6bn |
| USAreportable segment | revenue external | 2022-04-01 → 2023-03-31 | ¥36.6bn |
| USAreportable segment | segment profit | 2022-04-01 → 2023-03-31 | ¥930m |
| —segment total | revenue | 2022-04-01 → 2023-03-31 | ¥200.3bn |
| —segment total | revenue external | 2022-04-01 → 2023-03-31 | ¥200.3bn |
| —segment total | segment profit | 2022-04-01 → 2023-03-31 | ¥17.0bn |
| Reconciling Itemsreconciling | segment profit | 2021-04-01 → 2022-03-31 | ¥0 |
| Japanreportable segment | revenue | 2021-04-01 → 2022-03-31 | ¥163.8bn |
| Japanreportable segment | revenue external | 2021-04-01 → 2022-03-31 | ¥163.8bn |
| Japanreportable segment | segment profit | 2021-04-01 → 2022-03-31 | ¥32.4bn |
| USAreportable segment | revenue | 2021-04-01 → 2022-03-31 | ¥30.0bn |
| USAreportable segment | revenue external | 2021-04-01 → 2022-03-31 | ¥30.0bn |
| USAreportable segment | segment profit | 2021-04-01 → 2022-03-31 | −¥68.2bn |
| —segment total | revenue | 2021-04-01 → 2022-03-31 | ¥193.8bn |
| —segment total | revenue external | 2021-04-01 → 2022-03-31 | ¥193.8bn |
| —segment total | segment profit | 2021-04-01 → 2022-03-31 | −¥35.9bn |
| Japanreportable segment | employees | at 2023-03-31 | 73 pure |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,360
| Item | Context | Value | Unit |
|---|---|---|---|
| Footnotes directors and corporate auditors (text) | FilingDateInstant_Row5Member | Text · Plus | |
| Footnotes directors and corporate auditors (text) | FilingDateInstant_Row6Member | Text · Plus | |
| Outside directors and outside corporate auditors (text) | FilingDateInstant | Text · Plus | |
| Audits (text) | FilingDateInstant | Text · Plus | |
| Remuneration for directors and other officers (text) | FilingDateInstant | Text · Plus | |
| Remuneration etc paid by group to each director or other officer (text) | FilingDateInstant | Text · Plus | |
| Shareholdings (text) | FilingDateInstant | Text · Plus | |
| Name of group company holding largest amount of investment shares in group | CurrentYearInstant | Original text (Japanese)沢井製薬株式会社 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment largest holding company | CurrentYearInstant_Row1Member | Original text (Japanese)住友商事株式会社 | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment largest holding company | CurrentYearInstant_Row1Member | Original text (Japanese)原薬等の主要窓口商社として良好な関係を維持していくことの重要性を考慮して保有しております。 | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment largest holding company | CurrentYearInstant_Row1Member | Original text (Japanese)有 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment largest holding company | CurrentYearInstant_Row2Member | Original text (Japanese)日本化薬株式会社 | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment largest holding company | CurrentYearInstant_Row2Member | Original text (Japanese)医薬品の共同開発先として良好な関係を維持していくことの重要性を考慮して保有しております。 | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment largest holding company | CurrentYearInstant_Row2Member | Original text (Japanese)有 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment largest holding company | CurrentYearInstant_Row3Member | Original text (Japanese)株式会社ヤクルト本社 | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment largest holding company | CurrentYearInstant_Row3Member | Original text (Japanese)医薬品の共同開発先として良好な関係を維持していくことの重要性を考慮して保有しております。 | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment largest holding company | CurrentYearInstant_Row3Member | Original text (Japanese)無 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment largest holding company | CurrentYearInstant_Row4Member | Original text (Japanese)株式会社メディパルホールディングス | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment largest holding company | CurrentYearInstant_Row4Member | Original text (Japanese)有力医薬品卸として良好な関係を維持していくことの重要性を考慮して保有しております。 | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment largest holding company | CurrentYearInstant_Row4Member | Original text (Japanese)有 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment largest holding company | CurrentYearInstant_Row5Member | Original text (Japanese)アルフレッサ ホールディングス株式会社 | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment largest holding company | CurrentYearInstant_Row5Member | Original text (Japanese)有力医薬品卸として良好な関係を維持していくことの重要性を考慮して保有しております。 | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment largest holding company | CurrentYearInstant_Row5Member | Original text (Japanese)有 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment largest holding company | CurrentYearInstant_Row6Member | Original text (Japanese)株式会社メディカル一光グループ | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment largest holding company | CurrentYearInstant_Row6Member | Original text (Japanese)有力医薬品卸として良好な関係を維持していくことの重要性を考慮して保有しております。 | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment largest holding company | CurrentYearInstant_Row6Member | Original text (Japanese)有 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment largest holding company | CurrentYearInstant_Row7Member | Original text (Japanese)ダイト株式会社 | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment largest holding company | CurrentYearInstant_Row7Member | Original text (Japanese)製品製造に関する委受託契約先として良好な関係を維持していくことの重要性を考慮して保有しております。 | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment largest holding company | CurrentYearInstant_Row7Member | Original text (Japanese)有 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment largest holding company | CurrentYearInstant_Row8Member | Original text (Japanese)朝日印刷株式会社 | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment largest holding company | CurrentYearInstant_Row8Member | Original text (Japanese)添付資料等の発注先として良好な関係を維持していくことの重要性を考慮して保有しております。 | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment largest holding company | CurrentYearInstant_Row8Member | Original text (Japanese)有 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment largest holding company | CurrentYearInstant_Row9Member | Original text (Japanese)株式会社テクノ菱和 | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment largest holding company | CurrentYearInstant_Row9Member | Original text (Japanese)主要設備メンテナンス取引先として良好な関係を維持していくことの重要性を考慮して保有しております。 | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment largest holding company | CurrentYearInstant_Row9Member | Original text (Japanese)有 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment largest holding company | CurrentYearInstant_Row10Member | Original text (Japanese)株式会社三菱ＵＦＪフィナンシャル・グループ | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment largest holding company | CurrentYearInstant_Row10Member | Original text (Japanese)主要取引金融機関として良好な関係を維持していくことの重要性を考慮して保有しております。 | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment largest holding company | CurrentYearInstant_Row10Member | Original text (Japanese)有 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment largest holding company | CurrentYearInstant_Row11Member | Original text (Japanese)株式会社三井住友フィナンシャルグループ | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment largest holding company | CurrentYearInstant_Row11Member | Original text (Japanese)主要取引金融機関として良好な関係を維持していくことの重要性を考慮して保有しております。 | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment largest holding company | CurrentYearInstant_Row11Member | Original text (Japanese)有 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment largest holding company | CurrentYearInstant_Row12Member | Original text (Japanese)株式会社みずほフィナンシャルグループ | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment largest holding company | CurrentYearInstant_Row12Member | Original text (Japanese)主要取引金融機関として良好な関係を維持していくことの重要性を考慮して保有しております。 | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment largest holding company | CurrentYearInstant_Row12Member | Original text (Japanese)有 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment reporting company | CurrentYearInstant_Row1Member | Original text (Japanese)サスメド株式会社 | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row1Member | Original text (Japanese)同社のデジタルヘルスケア領域での技術や知見を当社グループの事業と融合させた協業の展開について検討を進めるため。 | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row1Member | Original text (Japanese)無 | |
| Description of fact that consolidated financial statements have been prepared in accordance with IFRS financial information | CurrentYearDuration | Text · Plus | |
| Regulations in accordance with which financial statements have been prepared financial information | CurrentYearDuration | Text · Plus | |
| Description of fact that financial statements have been prepared in accordance with special provision financial information | CurrentYearDuration | Original text (Japanese)また、当社は、特例財務諸表提出会社に該当し、財務諸表等規則第127条の規定により財務諸表を作成しております。 |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 20 of 20 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |